These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31629644)

  • 1. Infection prevention and control in cystic fibrosis: One size fits all The argument against.
    Smyth AR; Smith SJ; Rowbotham NJ
    Paediatr Respir Rev; 2020 Nov; 36():94-96. PubMed ID: 31629644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro con debates in clinical medicine infection prevention and control in cystic fibrosis: One size fits all? The argument in favour.
    Haggie S; Fitzgerald DA
    Paediatr Respir Rev; 2020 Nov; 36():97-99. PubMed ID: 32631758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.
    Govan JR
    J R Soc Med; 2000; 93 Suppl 38(Suppl 38):40-5. PubMed ID: 10911818
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
    Saiman L; Siegel J;
    Am J Infect Control; 2003 May; 31(3 Suppl):S1-62. PubMed ID: 12762292
    [No Abstract]   [Full Text] [Related]  

  • 6. Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review.
    Festini F; Buzzetti R; Bassi C; Braggion C; Salvatore D; Taccetti G; Mastella G
    J Hosp Infect; 2006 Sep; 64(1):1-6. PubMed ID: 16835001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current infection control practices used in Australian and New Zealand cystic fibrosis centers.
    Stockwell RE; Wood ME; Ballard E; Moore V; Wainwright CE; Bell SC
    BMC Pulm Med; 2020 Jan; 20(1):16. PubMed ID: 31952502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.
    Cogen JD; Onchiri F; Emerson J; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M
    Ann Am Thorac Soc; 2018 Jun; 15(6):702-709. PubMed ID: 29474110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures.
    Savant AP; O'Malley C; Bichl S; McColley SA
    BMJ Qual Saf; 2014 Apr; 23 Suppl 1():i73-i80. PubMed ID: 24608553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
    Elborn JS; Hodson M; Bertram C
    J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
    Smyth AR; Rosenfeld M
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD001912. PubMed ID: 28417451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiresistant pulmonary infection in cystic fibrosis--prevention is better than cure.
    Smyth A
    Lancet; 2005 Aug 6-12; 366(9484):433-5. PubMed ID: 16084235
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
    Govan JR; Brown AR; Jones AM
    Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenic bacteria in cystic fibrosis].
    Mariani-Kurkdjian P; Bingen E
    Arch Pediatr; 2003 Sep; 10 Suppl 2():342s-346s. PubMed ID: 14671932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection prevention and control in patients with cystic fibrosis (CF): Results from a survey in 35 German CF treatment centers.
    Meyer S; Nüßlein T; Nährlich L; Bend J; Gärtner B; Becker SL; Simon A
    J Cyst Fibros; 2020 May; 19(3):384-387. PubMed ID: 31680044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on antibiotics for infection control in cystic fibrosis.
    Kirkby S; Novak K; McCoy K
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):967-80. PubMed ID: 19803706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis.
    Ahmed MI; Mukherjee S
    Cochrane Database Syst Rev; 2016 Mar; 3():CD011581. PubMed ID: 27003247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.
    Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M
    J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconsidering isolation precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
    Morgan DJ; Kaye KS; Diekema DJ
    JAMA; 2014 Oct; 312(14):1395-6. PubMed ID: 25291571
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.